Breaking News

Covance Appoints VP and Global Therapeutic Head

By Kristin Brooks | January 21, 2014

Goldstein brings extensive research experience

Barry J. Goldstein, M.D., Ph.D., has been appointed vice president and global therapeutic area head at Covance’s expanded Cardiovascular, Metabolic, Endocrine and Renal unit of the Clinical Development Services business. Dr. Goldstein will join the Medical & Scientific Affairs leadership team and will be based in Princeton, NJ.
 
Dr. Goldstein joins the company from Merck, where he served as vice president in Clinical Research and therapeutic area head for diabetes and endocrinology. He also managed Merck’s Phase II-IV clinical development team for a portfolio including diabetes, obesity, osteoporosis, and women’s health, and provided input on proof-of-concept study designs, clinical trial strategies, protocol development, regulatory filings, lifecycle management activities, and pharmacovigilance and post-marketing studies.
 
“Barry brings significant endocrinology, metabolism and broad drug development experience to complement our existing cardiovascular expertise at Covance,” said Ken Somberg, chief medical officer and vice president, Clinical Development Services. “Barry is a noted leader in the field of diabetes mellitus and endocrinology. His leadership will help us expand our strategic vision in these key therapeutic areas, as well as provide critical scientific insight to our colleagues and our clients throughout the biopharmaceutical industry.”

blog comments powered by Disqus
  • 16th Annual $alary $urvey

    16th Annual $alary $urvey

    Tim Wright, Editor||June 3, 2015
    Welcome to Contract Pharma’s Sixteenth Annual Salary Survey! This year’s results are derived from more than 500 respondents f

  • Newsmakers: PCI

    Newsmakers: PCI

    Tim Wright, Editor||June 2, 2015
    PCI execs talk about the recent opening of the company’s new North American clinical facility, as well as other trends in the market

  • How Sterilization of Primary Packaging Influences the Results of E&L Studies

    How Sterilization of Primary Packaging Influences the Results of E&L Studies

    Thorsten Sogding, Daniel Canton, Daniel Haines, Uwe Rothhaar, SCHOTT Pharma Services ||June 2, 2015
    As the demands that are being placed on the quality and stability of medications continue to increase, the interactions that take place between the primary packaging container and filled drug product are becoming increasingly important